[Experimental study of interstitial chemotherapy with PYM delivered from a solid implantable biodegradable polymer against human tongue SCC in tumor-bearing nude mice].
OBJECTIVE
This study was to evaluate the antitumor efficacy of implantable sustained Pingyangmycin (PYM) release system as a polymer based biocompatible implant administrated interstitially in tumors on tumor-bearing nude mice.


METHODS
20 tumor-bearing nude mice established with Tca8113 cell line were divided into five groups .Interstitial chemotherapy (polymer rod each containing 0.1mg PYM was inserted into tumors through puncture needle with internal piston)was performed in mice of Group A, intravenous injection of PYM was made in mice of Group B, intratumoral injection of PYM was given in mice of Group C, polymer rod without PYM was inserted into tumors in Group D and normal saline was intravenously injected in mice of Group E as control. Same total dosage of PYM was given in Group A , B and C. Inhibition rate (IR) based on tumor measurement, apoptosis index (AI) of tumor cells based on TUNEL, apoptosis rate (AT) of tumor cells determined by flow cytometry and histopathological appearances were evaluated and analyzed in different groups. F test was used for statistical analysis by SAS 6.2 software package.


RESULTS
The results showed that RI,AT and AI in experimental group (Group A) was significantly higher than that in other groups (P<0.05) Histopathologically, the proliferation of the tumor cells was relatively suppressed in Group A.


CONCLUSIONS
Biodegradable PYM-polymer implant may be an optimistic form of drug delivery system in clinic and interstitial chemotherapy is especially suitable for tumors in oral-maxillofacial regions because of easy administration of the implant into the relatively superficial tumors in the regions.
Chen
Chuan-jun
CJ
Department of Oral and Maxillofacial Surgery, Anhui Provincial Hospital, Hefei 230001, Anhui Province, China.
Zhang
Zhi-yuan
ZY
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001761:Bleomycin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004343:Drug Implants / Q000627:therapeutic use*; D006801:Humans; D015552:Injections, Intralesional; D008819:Mice, Nude; D011108:Polymers
D004343:Drug Implants; D011108:Polymers; D001761:Bleomycin; C025703:bleomycetin